Copyright
©The Author(s) 2023.
World J Transplant. Feb 18, 2023; 13(2): 44-57
Published online Feb 18, 2023. doi: 10.5500/wjt.v13.i2.44
Published online Feb 18, 2023. doi: 10.5500/wjt.v13.i2.44
Figure 3 Crude patient survival and death-censored graft survival among four cohorts in the pre- and post-direct-acting antivirals eras.
Survival was presented in Kaplan-Meier curves and analyzed by log-rank tests. Multiple comparison was adjusted by Bonferroni correction. A: Crude patient survival in the pre-direct-acting antivirals (DAA) era; B: Crude death-censored graft survival (DCGS) in the pre-DAA era; C: Crude patient survival in the post-DAA era; D: crude DCGS in the post-DAA era. DAA: Direct-acting antivirals; HCV: Hepatitis C virus; DCGS: Death-censored graft survival.
- Citation: Yuan Q, Hong S, Leya G, Roth E, Tsoulfas G, Williams W, Madsen JC, Elias N. Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States. World J Transplant 2023; 13(2): 44-57
- URL: https://www.wjgnet.com/2220-3230/full/v13/i2/44.htm
- DOI: https://dx.doi.org/10.5500/wjt.v13.i2.44